This is a map, not medical advice, so talk to your own doctor before you change anything
The first GLP-1 drug, exenatide, was synthesized from exendin-4 , a peptide originally isolated from the saliva of the Gila monster lizard in the early 1990s and approved by the FDA in 2005.Over time, we got once-weekly versions (dulaglutide, semaglutide, etc.) and higher doses, which led to: Strong A1c lowering Substantial weight loss Cardiovascular benefits in high-risk patients with diabetes Where GLP-1s are clearly helpful Type 2 diabetes In type 2 diabetes, long-acting GLP-1 RAs: Lower A1c by roughly 11.5 percentage points Promote clinically meaningful weight loss Have low hypoglycemia risk Reduce heart attack and stroke in high-risk patients in multiple large trials For many with diabetes plus cardiovascular or kidney disease, a GLP-1 RA is now a core cardiometabolic drug , not just a glucose medication

Validate that signature dates are valid and not in the future, and optionally flag if the plan member signature date precedes the physician signature date by an unusual margin (or vice versa) indicating potential form assembly issues
Notably, many of the RDs in our focus groups were the first to identify and address the risk of refeeding syndrome and to lead sensitive conversations surrounding G-tube placement
Your healthcare provider should show you how to use Trulicity before you use it for the first time